rme.15.59.pdf (1.02 MB)
Using the cost-effectiveness of allogeneic islet transplantation to inform iPSC derived beta cell therapy reimbursement
journal contributionposted on 2015-09-29, 12:41 authored by Peter R.T. Archibald, David J. Williams
In the present study a cost-effectiveness analysis of Allogeneic Islet Transplantation was performed and the financial feasibility of a Human Induced Pluripotent Stem Cell (hiPSC) derived Beta Cell therapy was explored. Previously published cost and health benefit data for Islet Transplantation was utilised to perform the cost-effectiveness and sensitivity analyses. It was determined that, over a 9 year time horizon, Islet Transplantation would become cost saving and ‘dominate’ the comparator. Over a 20 year time horizon, Islet Transplantation would incur significant cost savings over the comparator (£59,000). Finally, assuming a similar cost of goods to Islet Transplantation and a lack of requirement for immunosuppression, a hiPSC-derived Beta Cell therapy would dominate the comparator over an 8 year time horizon.
This research was funded by Loughborough University and the Engineering and Physical Sciences Research Council (EPSRC).
- Mechanical, Electrical and Manufacturing Engineering
Published inRegenerative Medicine
CitationARCHIBALD, P.R.T. and WILLIAMS, D.J., 2015. Using the cost-effectiveness of allogeneic islet transplantation to inform iPSC derived beta cell therapy reimbursement. Regenerative Medicine, 10 (8), pp. 959-973.
PublisherFuture Medicine / © The Authors
- NA (Not Applicable or Unknown)
Publisher statementThis work is made available according to the conditions of the Creative Commons Attribution 4.0 International (CC BY 4.0) licence. Full details of this licence are available at: https://creativecommons.org/licenses/by/4.0/
NotesThis is an Open Access article published by Future Medicine and licensed under a Creative Commons Attribution 4.0 Unported License